PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Short Interest Down 33.8% in January

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totalling 30,300 shares, a decline of 33.8% from the December 31st total of 45,800 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average daily trading volume, of 27,500 shares, the days-to-cover ratio is currently 1.1 days.

PharmaCyte Biotech Stock Performance

Shares of PharmaCyte Biotech stock opened at $1.65 on Wednesday. PharmaCyte Biotech has a one year low of $1.39 and a one year high of $2.58. The company has a market cap of $11.49 million, a PE ratio of 3.11 and a beta of -0.22. The business has a 50-day simple moving average of $1.64 and a 200-day simple moving average of $1.75.

PharmaCyte Biotech (NASDAQ:PMCB) last posted its earnings results on Friday, December 13th. The company reported ($0.29) earnings per share for the quarter.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.